Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Johnson and Johnson
Moodys
Express Scripts

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,034,239

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,034,239 protect, and when does it expire?

Patent 6,034,239 protects ROZEREM and is included in one NDA.

This patent has thirty-four patent family members in nineteen countries.

Summary for Patent: 6,034,239
Title: Tricyclic compounds, their production and use
Abstract:A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.
Inventor(s): Ohkawa; Shigenori (Osaka, JP), Uchikawa; Osamu (Hyogo, JP), Fukatsu; Kohji (Hyogo, JP), Miyamoto; Masaomi (Hyogo, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:08/812,168
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,034,239
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 6,034,239

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ROZEREM ramelteon TABLET;ORAL 021782-001 Jul 22, 2005 AB RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,034,239

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-051491Mar 08, 1996
Japan8-183667Jul 12, 1996
Japan9-029185Feb 13, 1997

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.